Caren Deardorf insider trades

Open-market stock purchases and sales by Caren Deardorf, Director at Crinetics Pharmaceuticals, Inc, from SEC Form 4 filings since Jul 6, 2021.

Recent trades

DateStockTradeValue
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$1.4M
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$504K
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$2.3M
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$292K
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$1.1M
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$504K
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$545K
Sep 1, 2026CRNX Crinetics Pharmaceuticals, IncSold (not open market)$478K
Jun 18, 2026CRNX Crinetics Pharmaceuticals, IncBought (not open market)—
Jun 18, 2026CRNX Crinetics Pharmaceuticals, IncBought (not open market)—

Companies traded

  • CRNX Crinetics Pharmaceuticals, Inc: other filings, last Sep 1, 2026
  • MGTA Magenta Therapeutics, Inc: 1 sale, last Nov 30, 2022

Get free alerts when Caren Deardorf files a new trade →